Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,384 shares of the medical equipment provider’s stock after selling 1,115 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Zimmer Biomet were worth $473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Empowered Funds LLC boosted its stake in Zimmer Biomet by 50.6% during the 1st quarter. Empowered Funds LLC now owns 3,757 shares of the medical equipment provider’s stock worth $496,000 after purchasing an additional 1,262 shares during the last quarter. QRG Capital Management Inc. grew its stake in Zimmer Biomet by 62.4% during the 1st quarter. QRG Capital Management Inc. now owns 7,133 shares of the medical equipment provider’s stock valued at $941,000 after acquiring an additional 2,740 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in Zimmer Biomet by 6.2% in the 1st quarter. Bleakley Financial Group LLC now owns 2,271 shares of the medical equipment provider’s stock valued at $300,000 after acquiring an additional 132 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Zimmer Biomet by 17.4% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 246,088 shares of the medical equipment provider’s stock worth $32,479,000 after purchasing an additional 36,514 shares in the last quarter. Finally, Kingsview Wealth Management LLC boosted its holdings in shares of Zimmer Biomet by 22.4% during the 1st quarter. Kingsview Wealth Management LLC now owns 3,225 shares of the medical equipment provider’s stock worth $426,000 after purchasing an additional 590 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $108.85 on Friday. The company has a market cap of $21.67 billion, a P/E ratio of 20.69, a P/E/G ratio of 2.02 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock has a 50-day moving average of $106.04 and a two-hundred day moving average of $110.19.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the firm earned $1.65 EPS. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZBH shares. Robert W. Baird cut their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. BTIG Research reduced their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. UBS Group reduced their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Finally, Wolfe Research initiated coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.